A novel adenosine A1 and A2A receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs

Behavioural Brain Research

Volumn 194, Issue 2, 2008, Pages 152-161

  Mihara, Takuma ^a   Iwashita, Akinori ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adenosine receptor antagonist; ASP5854; Monkeys; Motor disability; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 [5 AMINO 3 (4 FLUOROPHENYL)PYRAZIN 2 YL] 1 ISOPROPYLPYRIDINE 2(1H) ONE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; ASP 5854; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; SELEGILINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL;

AMINOPYRIDINES; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS; MPTP POISONING; PIPERAZINES; RECEPTORS, PURINERGIC; TIME FACTORS;

EID: 50549101921     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2008.06.035     Document Type: Article

References (47)

1. Bara-Jimenez W., Sherzai A., Dimitrova T., Favit A., Bibbiani F., Gillespie M., et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
2. Bedard M.A., Pillon B., Dubois B., Duchesne N., Masson H., and Agid Y. Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome. Brain Cognit 40 (1999) 289-313
3. Blanchet P.J., Konitsiotis S., and Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13 (1998) 798-802
4. Chen J.J., and Swope D.M. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 27 (2007) 161S-173S
5. Close S.P., Elliott P.J., Hayes A.G., and Marriott A.S. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology (Berl) 102 (1990) 295-300
6. Crosby N, Deane KH, Clarke CE, Amantadine in Parkinson's disease, Cochrane database of systematic reviews (Online), 2003; CD003468.
7. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., and Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 21 (1997) 455-468
8. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 (1979) 249-254
9. Deleu D., Northway M.G., and Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 41 (2002) 261-309
10. Domino E.F., and Ni L. Trihexyphenidyl potentiation of l-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys. Exp Neurol 152 (1998) 238-242
11. Dubois B., Pilon B., Lhermitte F., and Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol 28 (1990) 117-121
12. Ferre S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20 (1997) 482-487
13. Ferre S., von Euler G., Johansson B., Fredholm B.B., and Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 88 (1991) 7238-7241
14. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler E.M., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 14 (1992) 186-195
15. Floran B., Gonzalez B., Floran L., Erlij D., and Aceves J. Interactions between adenosine A(2a) and dopamine D2 receptors in the control of [(3)H]GABA release in the globus pallidus of the rat. Eur J Pharmacol 520 (2005) 43-50
16. Fukuzaki K., Kamenosono T., Kitazumi K., and Nagata R. Effects of ropinirole on motor behavior in MPTP-treated common marmosets. Pharmacol Biochem Behav 67 (2000) 121-129
17. Hauber W., Neuscheler P., Nagel J., and Muller C.E. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci 14 (2001) 1287-1293
18. Hill M.P., Ravenscroft P., Bezard E., Crossman A.R., Brotchie J.M., Michel A., et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Journal Pharmacol Exp Ther 310 (2004) 386-394
19. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
20. Jarvis M.F., and Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol 168 (1989) 243-246
21. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43 (1998) 507-513
22. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 65 (2001) 1447-1457
23. Kaseda S., Nomoto M., and Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res 815 (1999) 44-50
24. Koga K., Kurokawa M., Ochi M., Nakamura J., and Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 408 (2000) 249-255
25. Kurokawa M., Kirk I.P., Kirkpatrick K.A., Kase H., and Richardson P.J. Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 113 (1994) 43-48
26. LeWitt P.A., Guttman M., Tetrud J.W., Tuite P.J., Mori A., Chaikin P., et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63 (2008) 295-302
27. Libert F., Schiffmann S.N., Lefort A., Parmentier M., Gerard C., Dumont J.E., et al. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J 10 (1991) 1677-1682
28. Loschmann P.A., Smith L.A., Lange K.W., Jahnig P., Jenner P., and Marsden C.D. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl) 109 (1992) 49-56
29. Mihara T., Mihara K., Yarimizu J., Mitani Y., Matsuda R., Yamamoto H., et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther 323 (2007) 708-719
30. Mihara T., Noda A., Arai H., Mihara K., Iwashita A., Murakami Y., et al. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in Rhesus monkeys: relationship to anticataleptic effect. J Nucl Med (2008)
31. Nash J.E., and Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 20 (2000) 7782-7789
32. Nomoto M., Iwata S.I., Kaseda S., Fukuda T., and Nakagawa S. Increased dopamine turnover in the putamen after MPTP treatment in common marmosets. Brain Res 767 (1997) 235-238
33. Nomoto M., Jenner P., and Marsden C.D. The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 93 (1988) 275-280
34. Nomoto M., Kita S., Iwata S.I., Kaseda S., and Fukuda T. Effects of acute or prolonged administration of cabergoline on parkinsonism induced by MPTP in common marmosets. Pharmacol Biochem Behav 59 (1998) 717-721
35. Perry E.K., Kilford L., Lees A.J., Burn D.J., and Perry R.H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 54 (2003) 235-238
36. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J Neurochem 92 (2005) 433-441
37. Rose S., Jackson M.J., Smith L.A., Stockwell K., Johnson L., Carminati P., et al. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of l-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546 (2006) 82-87
38. Saji H., Iida Y., Kawashima H., Ogawa M., Kitamura Y., Mukai T., et al. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. Anal Sci 19 (2003) 67-71
39. Schelosky L., Benke T., and Poewe W.H. Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. J Neural Transm Suppl 33 (1991) 125-132
40. Silkis I. The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia. Bio Systems 59 (2001) 7-14
41. Starr M.S., and Starr B.S. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. J Neural Transm 9 (1995) 31-43
42. Temlett J.A., Chong P.N., Oertel W.H., Jenner P., and Marsden C.D. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 156 (1988) 197-206
43. Thanvi B., Lo N., and Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83 (2007) 384-388
44. van Kempen G.M., Janjua R., and Roos R.A. Effect of disease and drug treatment on blood serotonin and monoamine oxidase B activity in Parkinson's disease. Clin Neurol Neurosurg 97 (1995) 131-133
45. Villanueva-Toledo J., Moo-Puc R.E., and Gongora-Alfaro J.L. Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neurosci Lett 346 (2003) 1-4
46. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 21 (2006) 1879-1891
47. Waters C.M., Hunt S.P., Jenner P., and Marsden C.D. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Neuroscience 23 (1987) 1025-1039